Current experimental methods to investigate the impact of specialized pro-resolving lipid mediators on Sjögren's syndrome.

Autor:	Dos Santos HT; Bond Life Sciences Center, University of Missouri, Columbia, MO, United States.; Department of Otolaryngology-Head and Neck Surgery, School of Medicine, University of Missouri, Columbia, MO, United States., Nam K; Bond Life Sciences Center, University of Missouri, Columbia, MO, United States.; Department of Otolaryngology-Head and Neck Surgery, School of Medicine, University of Missouri, Columbia, MO, United States., Gil D; Department of Surgery, School of Medicine, University of Missouri, Columbia, MO, United States.; Department of Molecular Microbiology and Immunology, School of Medicine, University of Missouri, Columbia, MO, United States.; Department of Biological and Biomedical Engineering, College of Engineering, University of Missouri, Columbia, MO, United States., Yellepeddi V; Division of Clinical Pharmacology, Department of Pediatrics, School of Medicine, University of Utah, Salt Lake City, UT, United States.; Department of Molecular Pharmaceutics, College of Pharmacy, University of Utah, Salt Lake City, UT, United States., Baker OJ; Bond Life Sciences Center, University of Missouri, Columbia, MO, United States.; Department of Otolaryngology-Head and Neck Surgery, School of Medicine, University of Missouri, Columbia, MO, United States.; Department of Biochemistry, University of Missouri, Columbia, MO, United States.
Jazyk:	angličtina
Zdroj:	Frontiers in immunology [Front Immunol] 2023 Jan 12; Vol. 13, pp. 1094278. Date of Electronic Publication: 2023 Jan 12 (Print Publication: 2022).
DOI:	10.3389/fimmu.2022.1094278
Abstrakt:	Sjögren's syndrome is a chronic inflammatory autoimmune disease characterized by diminished secretory function of the exocrine glands. Although extensive investigation has been done to understand Sjögren's syndrome, the causes of the disease are as yet unknown and treatments remain largely ineffective, with established therapeutic interventions being limited to use of saliva substitutes with modest effectiveness. A primary feature of Sjögren's syndrome is uncontrolled inflammation of exocrine tissues and previous studies have demonstrated that lipid-based specialized pro-resolving mediators reduce inflammation and restores tissue integrity in salivary glands. However, these studies are limited to a single specialized pro-resolving lipid mediator's family member resolvin D1 or RvD1 and its aspirin-triggered epimer, AT-RvD1. Consequently, additional studies are needed to explore the potential benefits of other members of the specialized pro-resolving lipid mediator's family and related molecules ( e.g. , additional resolvin subtypes as well as lipoxins, maresins and protectins). In support of this goal, the current review aims to briefly describe the range of current experimental methods to investigate the impact of specialized pro-resolving lipid mediators on Sjögren's syndrome, including both strengths and weaknesses of each approach where this information is known. With this article, the possibilities presented by specialized pro-resolving lipid mediators will be introduced to a wider audience in immunology and practical advice is given to researchers who may wish to take up this work. Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. (Copyright © 2023 dos Santos, Nam, Gil, Yellepeddi and Baker.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu